NCT06927050 Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers
| NCT ID | NCT06927050 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2025-04-21 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2025-04-21 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.
Eligibility Criteria
Inclusion Criteria: Patients: * Patients seen in consultation from 12/1/2024-6/1/2025 * Patients aged 18 years to 100 years old * Patients with a malignancy of breast or head and neck * English speaking patients * Patients being treated with definitive intent * Patients treated at NYU Langone Health for their malignancy * Willing and able to provide consent Caregivers: * Any adult caregiver(s) (aged 18 years to 100 years old) to a patient who fulfills the inclusion and exclusion criteria above. * Willing and able to provide consent Providers: * Doctors and nurse practitioners in medical oncology and radiation oncology, and in the ear nose throat (ENT) department. * Willing and able to provide consent * aged 18 years to 100 years old Exclusion Criteria: Patients: * Patients with any other site of disease other than listed above * Non-English-speaking patients, as the tool is currently available in English only. Translation into additional languages such as Spanish and Russian is currently in process. * Patient unable to complete the survey portion of the study independently Caregivers: • Unable to complete the survey portion of the study independently
Contact & Investigator
Jason Domogauer, MD, PhD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06927050 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06927050 currently recruiting?
Yes, NCT06927050 is actively recruiting participants. Contact the research team at Jason.Domogauer@nyulangone.org for enrollment information.
Where is the NCT06927050 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06927050 clinical trial?
NCT06927050 is sponsored by NYU Langone Health. The principal investigator is Jason Domogauer, MD, PhD at NYU Langone Health. The trial plans to enroll 86 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.